Journal of Jianghan University(Natural Science Edition) ›› 2019, Vol. 47 ›› Issue (4): 357-360.doi: 10.16389/j.cnki.cn42-1737/n.2019.04.011

Previous Articles     Next Articles

A Case Report of B-cell Lymphoma Ⅳa Period Treated by BTK Inhibitor Ibrutinib

SUN Qiong1，WANG Hongxiang*2，CHEN Li2，GUO Liyin2   

  1. 1. School of Medicine，Jianghan University，Wuhan 430056，Hubei，China；2. Department of Hematology，The Central Hospital of Wuhan，Wuhan 430014，Hubei，China
  • Online:2019-08-28 Published:2019-07-10
  • Contact: WANG Hongxiang

PDF

216

Abstract: Objective To understand the efficacy of BTK inhibitor Ibrutinib in the treatment of recurrent/refractory B-cell lymphoma，and to provide a chemotherapy-free treatment for B-cell lymphoma. Methods Retrospective analysis on clinical data and the BTK inhibitor Ibrutinib treatment effect of 1 patient of B-cell lymphoma Ⅳa period with unfortunate effect after multiple courses of chemotherapy. Results The patient was sensitive to Ibrutinib treatment and had a good prognosis. Conclusion The new targeted drug BTK inhibitor，Ibrutinib，has good therapeutic effects on refractory or recurrent Bcell lymphoma.

Key words: B-cell lymphoma, BTK inhibitor, Ibrutinib

CLC Number: